Dr David Gibson is a biochemist with over 15 years of experience in arthritis clinical research. He was awarded a PhD from Queen’s University Belfast in 2001 for work on drugs to reduce brain cancer spread. Dr Gibson has over 50 publications and has held research posts in both the USA and UK. As Chief Scientific Officer he oversees basic science and pre-clinical research programmes to screen compounds in disease models and advance promising leads through to rigorous clinical trials. His personal research focus with GreenLight Medicines is to identify phytocannabinoids which reduce inflammation and pain in arthritis.